Ajanta Pharma’s growth story gets a semaglutide boost
Given Ajanta’s improving business mix and robust cash generation, its share valuation appears reasonable for a company transitioning into a cleaner, higher-visibility healthcare compounder.
Given Ajanta’s improving business mix and robust cash generation, its share valuation appears reasonable for a company transitioning into a cleaner, higher-visibility healthcare compounder.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
